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Summary
Dopamine neurons in the ventral tegmental area (VTA)
represent a critical site of synaptic plasticity induced
by addictive drugs. Orexin/hypocretin-containing neu-
rons in the lateral hypothalamus project to the VTA,
and behavioral studies have suggested that orexin
neurons play an important role in motivation, feeding,
and adaptive behaviors. However, the role of orexin
signaling in neural plasticity is poorly understood.
The present study shows that in vitro application of
orexin A induces potentiation of N-methyl-D-aspartate
receptor (NMDAR)-mediated neurotransmission via a
PLC/PKC-dependent insertion of NMDARs in VTA do-
pamine neuron synapses. Furthermore, in vivo admin-
istration of an orexin 1 receptor antagonist blocks
locomotor sensitization to cocaine and occludes
cocaine-induced potentiation of excitatory currents in
VTA dopamine neurons. These results provide in vitro
and in vivo evidence for a critical role of orexin signal-
ing in the VTA in neural plasticity relevant to addiction.
Introduction
Drugs of abuse can alter synaptic plasticity in the meso-
limbic dopamine system, a region that is implicated in a
variety of addictive behaviors. In particular, long-lasting
changes at excitatory synapses in the nucleus accum-
bens and the VTA result from in vivo administration of
drugs of abuse (Fitzgerald et al., 1996; Thomas et al.,
2001; Ungless et al., 2001; Borgland et al., 2004). The lat-
eral hypothalamus (LH) sends a substantial projection to
the VTA (Fadel and Deutch, 2002; Baldo et al., 2003) and
is a critical element in motivation and reward circuits
activated by drugs of abuse, including cocaine (Wise,
1996).
Orexins (hypocretins) are neuropeptides synthesized
in neurons of the LH that can elicit arousal, feeding,
and appetitive behaviors (DeLecea et al., 1998; Sakurai
et al., 1998). There are two known orexins, A and B,
whose actions are mediated by two G protein-coupled
receptors, termed orexin receptor type 1 (OXR1) and
type 2 (OXR2); OXR1 shows higher affinity for orexin A,
while OXR2 shows equal affinity for the two ligands
(Sakurai et al., 1998).
Dopamine neurons in the VTA are critical for a similar
repertoire of motivated behaviors. In addition, excitatory
*Correspondence: bonci@itsa.ucsf.edusynaptic transmission in VTA dopamine neurons is
an important locus of neural plasticity induced by psy-
chostimulant administration. Several lines of evidence
suggest that orexin modulates dopaminergic neuro-
transmission. First, terminals of LH orexin neurons are
apposed to dendrites and somata of dopaminergic
VTA neurons (Fadel and Deutch, 2002). Second, the do-
pamine receptor antagonist haloperidol blocks hyperlo-
comotion and stereotypy induced by intracerebroven-
tricular orexin (Nakamura et al., 2000). Finally, orexin
increases the firing rate of VTA neurons (Korotkova
et al., 2003). Taken together, these results suggest that
endogenous orexin signaling in dopamine neurons is
an important substrate for the expression of motivated
behaviors. However, the contribution of orexin signaling
to VTA neural plasticity has not been investigated.
Glutamatergic transmission in the VTA plays a key role
in neural plasticity relevant to addiction (Carlezon and
Nestler, 2002; Kauer, 2004). In particular, the induction
of behavioral sensitization, a model used to assess
addictive substances, is dependent upon activation of
N-methyl-D-aspartate receptors (NMDARs) in the VTA
(Vanderschuren and Kalivas, 2000). NMDARs mediate
long-term plasticity at a variety of excitatory synapses,
and their activation promotes burst firing in VTA neurons
and optimizes dopamine release (Komendantov et al.,
2004). To elucidate potential contributions of orexin sig-
naling to neural plasticity in the VTA, we examined the
effects of orexin A signaling on excitatory synapses of
VTA dopamine neurons.
Results
Orexin A Potentiates NMDAR EPSCs in Dopamine
Neurons
Excitatory postsynaptic currents (EPSCs) were re-
corded from VTA neurons in rat midbrain slices. EPSCs
were evoked while holding neurons in voltage clamp at
+40 mV. Measurements were taken 20 ms after the stim-
ulus artifact, a time point at which the glutamatergic
EPSC is mediated purely by NMDARs. Bath application
of orexin A for 5 min resulted in a 49%6 9% potentiation
of NMDAR-mediated EPSCs (Figure 1A, n = 12, 10/12
neurons had potentiation greater than 10%). This poten-
tiation was concentration dependent (Figure 1B, 1 nM:
5% 6 1%, n = 6; 10 nM: 18% 6 3%, n = 6; 100 nM:
42% 6 5%, n = 6) and was significantly inhibited by
the selective OXR1 receptor antagonist SB 334867
(Figure 1C, 1 mM, n = 8, p < 0.01) although not completely
blocked, suggesting the presence of OXR2 as well.
AMPAR-mediated EPSCs recorded at 270 mV were
not changed by orexin A (Figure 1D, n = 8). Application
of orexin A (100 nM) for 30 min resulted in a 74% 6
16% potentiation of NMDAR EPSCs that lasted longer
than 40 min after washout (Figure 1E, n = 6). Orexin A-
induced potentiation of NMDAR EPSCs, but not AMPAR
EPSCs, suggests that orexin-mediated potentiation
occurs through a postsynaptic mechanism.
The VTA is composed of a heterogeneous collection
of cell types, distinguished in part by neurotransmitter
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590Figure 1. Orexin A Potentiates NMDAR-Mediated Synaptic Transmission in VTA Dopamine Neurons
(A) Orexin A (100 nM) increases NMDAR EPSCs evoked at +40 mV (n = 12, 10/12 neurons significantly potentiated). Inset shows representative
traces of NMDAR EPSCs before and 25 min after application of orexin A. Scale bars, 50 pA, 50 ms.
(B) Orexin A dose-dependently increases NMDAR EPSCs. Each bar represents the mean and SEM of EPSCs over a period of 2 min, 25 min after
application of orexin A at concentrations of 1 (n = 6, p < 0.05), 10 (n = 6, p < 0.001), and 100 nM (n = 6; p < 0.001, one-way ANOVA, peak concen-
tration effect versus baseline).
(C) Orexin A-mediated increase in NMDAR EPSCs is blocked by the selective OXR1 antagonist SB 334857 (1 mM; n = 8).
(D) Orexin A (100 nM) does not increase AMPAR EPSCs evoked at270 mV (n = 8). Inset shows representative traces of AMPAR EPSCs before and
25 min after application of orexin A. Scale bars, 20 pA, 20 ms.
(E) After a 30 min application, orexin A (100 nM) increases NMDAR EPSCs for a prolonged period of time (n = 6).
(F) Orexin A increases NMDAR EPSCs in TH-positive cells (7/8 TH+ neurons were orexin A responders, 1/8 TH+ did not respond, and 2/2
were TH2 and nonresponders). TH was labeled with anti-tyrosine hydroxylase antibodies and FITC. Biocytin was labeled with streptavidin-
conjugated Texas Red.
Error bars represent SEM.content. In addition to principal neurons, which are
mostly dopaminergic, there are secondary and tertiary
neurons that are mostly GABAergic (Cameron et al.,
1997; Margolis et al., 2003). To determine whether the
neurons showing orexin A-induced potentiation were
indeed dopaminergic, we filled neurons with biocytin
while recording EPSCs and subsequently processed
slices for tyrosine hydroxylase (TH). In TH-containing
neurons, orexin A potentiated NMDAR responses in 7/8
neurons (Figure 1F). Of the two neurons that did not
express TH, neither responded to orexin A. Thus, orexinA-induced potentiation of NMDAR-mediated EPSCs is
found primarily in VTA dopamine-containing neurons.
Orexin A Potentiates NMDAR EPSCs via a
PKC/PLC-Dependent Mechanism
In the next set of experiments, we sought to identify the
intracellular pathway through which OXR1 activation
leads to NMDAR potentiation. We loaded the patch
pipette with the PLC inhibitor U-73122 (1 mM, Figures 2A
and 2C, n = 6) or the PKC inhibitor chelerythrin (1 mM, Fig-
ures 1A and 1B, n = 6). In both cases, the potentiation of
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(A) Intracellular application of the phospholipase C inhibitor U73122 (filled circles, 1 mM, n = 6) or chelerythrin, a protein kinase C inhibitor (open
circles, 1 mM, n = 6), blocked orexin A-mediated potentiation of NMDAR EPSCs.
(B) An example trace of NMDAR EPSCs recorded in the presence of chelerythrin.
(C) An example recording of NMDAR EPSCs in the presence of U73122.
(D) Intracellular application of the protein kinase A inhibitor PKI (filled squares, 20 mM, n = 8) or the cAMP inhibitor Rp-cAMPS (open squares,
100 mM, n = 5) did not block orexin A-mediated potentiation of NMDAR EPSCs.
(E) An example trace of NMDAR EPSCs recorded in the presence of rp-cAMPS.
(F) An example recording of NMDAR EPSCs in the presence of PKI.
Error bars represent SEM.NMDAR-mediated EPSCs by 100 nM orexin A was com-
pletely blocked. Next, the protein kinase A inhibitor PKI
(20 mM, Figures 2D and 2F, n = 8) or Rp-cAMPs, a blocker
of cAMP (100mM, Figures 2D and 2E, n = 5), was added to
the patch pipette. In these experiments, robust potentia-
tion of NMDAR-mediated EPSCs occurred after orexin A
application. Taken together, these data indicate that
orexin A potentiates NMDARs in VTA dopamine neurons
through a PLC/PKC-dependent pathway.
Orexin A Modulates NMDAR Subunit Composition
NMDARs are composed of an obligatory NR1 subunit
and at least one NR2A, -B, -C, or -D subunit (Cull-Candy
et al., 2001). Changes in NMDAR subunit composition
confer distinct gating and pharmacological properties
on heteromeric NMDARs (Cull-Candy et al., 2001), and
a switch in subunit composition may alter synaptic func-
tion (Liu et al., 2004; Erreger et al., 2005). We therefore
sought to determine which type of NR2 subunit medi-
ates orexin A-induced potentiation of NMDA responses.
Bath application of the NR2A/C antagonist NVP-
AAM077 (0.4 mM; Liu et al., 2004; PEAQX, Feng et al.,
2004) inhibited NMDAR EPSCs by 54% 6 7% and did
not cause any further decrease of the current over the
duration of application (40 min, n = 6). The ability of
100 nM orexin A to potentiate NMDAR-mediated EPSCs
was significantly reduced in the presence of NVP-
AAM077 (Figure 3A, n = 7, maximum potentiation =
20% 6 6%, p < 0.05). To determine whether the NR2A/
C antagonist could block expression of orexin A-medi-
ated potentiation of NMDAR EPSCs, we applied NVP-
AAM077 (0.4 mM) during the peak increase of NMDAR
EPSCs induced by 100 nM orexin A application. Accord-ingly, NVP-AAM077 blocked orexin-mediated potentia-
tion of NMDAR EPSCs (Figure 3B, n = 6, remaining cur-
rent = 87% 6 11%). Further, we tested the effects of
orexin A in the presence of Zn2+, a high-affinity selective
inhibitor of NR1-NR2A receptors (Paoletti et al., 1997).
Zn2+ inhibited NMDAR EPSCs by 13% 6 8% (100 nM,
Figure 3C, n = 6) and by 29% 6 9% (300 nM, Figure 3C,
n = 5, p < 0.05). Potentiation of NMDARs was sig-
nificantly reduced in the presence of Zn2+ (Figure 3C,
n = 5, maximum potentiation = 14% 6 4%, p < 0.05).
To determine the potential involvement of NR2B-con-
taining subunits in orexin A-mediated potentiation of
NMDAR EPSCs, we measured orexin A responses in
the presence of the bath-applied NR2B antagonist ifen-
prodil (3 mM). The remaining current after ifenprodil
application was 71% 6 6%. In the absence of NR2B-
containing NMDAR, orexin A (100 nM) potentiated
NMDAR-mediated EPSCs by 36% to a maximum ampli-
tude of 107% 6 16% (Figure 3D, n = 6) of baseline
EPSCs. When both NR2A/C and NR2B inhibitors were
coapplied, orexin A (100 nM) potentiation of NMDAR
EPSCs was largely inhibited (Figure 3E, n = 6, orexin
potentiation: 32% 6 5% to 45% 6 12%, p > 0.05). To
determine whether the residual potentiation observed
in the presence of NVP-AAM077 or Zn2+ could be
blocked, we recorded the effects of orexin A after co-
application of the NR2A/C and NR2B inhibitors in addi-
tion to the NR2C/D-preferring antagonist PPDA (1 mM;
Feng, et al., 2004). PPDA further inhibited NMDAR
EPSCs by an additional 10% (remaining current =
14% 6 2.2%, n = 6, Figure 3F), and orexin A (100 nM)
did not alter the remaining current in the presence of
these blockers.
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(A) After bath application of NVP-AAM077 (0.4 mM), orexin A-mediated potentiation of NMDAR EPSCs was 20% 6 6% (n = 7).
(B) Expression of orexin A-mediated potentiation of NMDAR EPSCs was reversed by application of NVP-AAM077 (n = 6).
(C) Orexin A-mediated potentiation was mostly blocked in the presence of the selective NR2A inhibitor Zn2+ (300 nM, n = 5).
(D) Orexin A-mediated potentiation was not affected after bath application of the NR2B subunit-selective antagonist ifenprodil (3 mM; n = 6).
(E) After NVP-AAM077 (0.4 mM) and ifenprodil (3 mM) coapplication, orexin A (100 nM) potentiation of NMDAR EPSCs was blocked (n = 6).
(F) After coapplication of NVP-AAM077 (0.4 mM) and ifenprodil (3 mM), PPDA (1 mM) further inhibited NMDAR current and blocked orexin A (100
nM) mediated NMDAR potentiation (n = 6).
Error bars represent SEM.Orexin A Translocates NMDARs to the Synapse
Activation of PKC is implicated in NMDAR-dependent
long-term potentiation (Malinow et al., 1989), and it
modulates NMDAR trafficking to the membrane (Lan
et al., 2001; Scott et al., 2001; Fong et al., 2002). NMDARs
can translocate from intracellular or extrasynaptic pools
to synaptic sites (Lan et al., 2001; Tovar and Westbrook,
2002). Therefore, orexin A-mediated potentiation of
NMDAR EPSCs might be due to movement of NMDARs
from intracellular or extrasynaptic sites to the synapse.
Because MK-801 is an activity-dependent and irre-
versible NMDAR antagonist (Rosemund et al., 1993),
we took advantage of its properties to block only synap-
tic NMDARs that opened in response to synaptically re-
leased glutamate. We applied MK-801 (10 mM; Tovar andWestbrook, 2002) to VTA slices in the absence of stimu-
lation to equilibrate bath concentration. MK-801 pro-
gressively blocked NMDAR-EPSCs during the 0.1 Hz
stimulation. Approximately 5% of the current remained
after MK-801 application. We then washed out the un-
bound MK-801 in the absence of stimulation for 40 min
in control neurons (n = 5). In a separate group of slices,
we applied orexin A (100 nM, n = 6) for 5 min during the
washout period. Next, we stimulated synaptic activity
and observed that the maximal NMDAR amplitude in
orexin A-treated neurons was significantly greater than
in controls (Figures 4A and 4B, maximum current orexin:
40%6 17%, control: 5%6 1%, p < 0.05). In another set
of experiments, we first coapplied NMDA (500 mM) with
MK-801 (20 mM) to block all synaptic and extrasynaptic
Orexin A Mediates Dopamine Neuron Plasticity
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(A) Activity-dependent NMDAR antagonist MK-801 (10 mM) was applied to VTA cells in the absence of stimulation until bath concentration equil-
ibrated. The stimulator was switched on and MK-801 progressively blocked NMDAR EPSCs. Once EPSCs were blocked, stimulation was ceased
for 40 min while MK-801 was washed out. Application of orexin A (100 nM, filled squares, n = 6) during this washout period induced a significant
potentiation of NMDAR-mediated EPSCs (control: open circles, n = 5, p < 0.05, t test comparing averaged data from 61–67 min of control to
orexin-treated cells).
(B) An example recording of EPSCs during and after the application of MK-801.
(C) MK-801 (20 mM) was coapplied with NMDA (500 mM) in the absence of stimulation to block both synaptic and extrasynaptic receptors. When
the stimulator was turned on, NMDAR currents were fully blocked. MK-801 and NMDA were washed out in the absence of stimulation. Applica-
tion of orexin A (100 nM, filled circles, n = 6) during this washout period induced a significant potentiation of NMDAR-mediated EPSCs compared
to controls (open circles, n = 6, p < 0.05).
(D) An example recording of NMDAR EPSCs during and after coapplication of MK-801 and NMDA.
Error bars represent SEM.NMDARs. Then, we applied orexin A for 5 min during the
washout of MK-801 and NMDA in the absence of stimu-
lation (Figures 4C and 4D). After 15 min washout of
orexin, we stimulated synaptic activity and found the
maximal NMDAR amplitude in orexin A-treated neurons
was again significantly greater than in controls (Figures
4C and 4D, maximum current orexin: 20% 6 2%, n = 6;
control: 7% 6 2%, n = 6, p < 0.05). These data indicate
that orexin A potentiates NMDAR EPSCs, at least par-
tially, by promoting movement of intracellular NMDARs
to the synapse.
Orexin A Causes Late-Phase AMPAR-Mediated
Plasticity and Facilitates Cocaine-Induced
Potentiation of Excitatory Inputs to VTA Neurons
Psychostimulants produce a form of experience-depen-
dent plasticity known as behavioral sensitization, where-
by animals exhibit a long-lasting increase in the locomo-
tor-activating effects of the drug. This drug-induced
locomotor effect is accompanied by increased motiva-
tion for drug intake and enhanced drug reward (Shippen-berg and Heidbreder, 1995; Nestler, 2001; Kim et al.,
2004). Behavioral sensitization is mediated by increased
synaptic output of VTA dopamine neurons and alter-
ations of dopamine and glutamate effects in the nucleus
accumbens and prefrontal cortex (Vanderschuren and
Kalivas, 2000). Potentiation of NMDARs is critical for
the development of cocaine-mediated behavioral sensi-
tization, and long-term plasticity at excitatory synapses
can be observed with cocaine treatment (Vanderschuren
and Kalivas, 2000). This long-term plasticity is evident
as a persistent increase in the ratio of AMPA to NMDA-
mediated synaptic currents of VTA neurons (Ungless
et al., 2001; Saal et al., 2003; Borgland et al., 2004).
We investigated whether orexin signaling in the VTA
is required for the long-term plasticity associated with
the development of behavioral sensitization. We exam-
ined long-term synaptic plasticity at excitatory synap-
ses on VTA neurons 24 hr after a 5 day treatment of
cocaine (15 mg/kg) or saline (0.9%), a time course shown
to induce long-lasting locomotor sensitization to co-
caine (Thomas et al., 2001), with or without the OXR1
Neuron
594Figure 5. OXR1 Antagonist SB 334867 Blocks
Cocaine-Associated Plasticity in the VTA
(A) Rats were treated for 5 days with i.p. injec-
tions of either saline (open bars) or cocaine
(closed bars, 15 mg/kg). Cocaine treatment
(n = 4) increased the AMPAR/NMDAR ratio
compared to the saline-treated rats (n = 4,
p < 0.05, t test). In the presence of preadmin-
istered SB 334867 (10 mg/kg, i.p.), cocaine-
induced enhancement of the AMPAR/
NMDAR ratio, measured in VTA slices 24 hrs
later, was blocked by SB 334867 (saline, n =
5; cocaine, n = 11, p > 0.05, t test).
(B) Orexin A (100 nM) was bath applied for
5 min, and slices were recorded 15 min later
or at 3–4 hr after orexin application. AMPAR/
NMDAR ratio was significantly increased
3–4 hr after orexin A application (n = 8) com-
pared to control (n = 8) or 15 min after orexin
A exposure (n = 8, p < 0.01). Bars represent
mean and SEM.antagonist SB 334867 (10 mg/kg, Figure 5). To assay for
synaptic plasticity, we compared the relative contribu-
tion of AMPARs and NMDARs to EPSCs recorded in
VTA dopamine cells. Consistent with the potentiation
observed following acute and 7 day cocaine treatments
(Borgland et al., 2004), 5 day treatment with cocaine po-
tentiated the AMPAR/NMDAR ratio compared to saline
controls (Figure 5A, saline: 0.4 6 0.07, n = 4; cocaine:
0.8 6 0.1, n = 4, p < 0.05). This potentiation of synaptic
plasticity was blocked by 5 day treatment with the OXR1
antagonist SB 334867 administered 15 min prior to
cocaine or saline (Figure 5A, saline + SB334867: 0.4 6
0.02, n = 5 versus cocaine + SB334867: 0.5 6 0.08, n =
11, p > 0.05). Since OXR1 antagonists block cocaine-
mediated potentiation of the AMPAR/NMDAR ratio,
orexin A may either facilitate cocaine-mediated synaptic
plasticity or enhance synaptic transmission itself. We
tested whether a 5 min orexin A application caused
changes in AMPAR/NMDAR ratio either 15 min or
3–4 hr after application (Figure 5B). Orexin A (100 nM)
decreased AMPAR/NMDAR ratio 15 min after treatment
(control: 0.44 6 0.06, n = 8 versus 15 min: 0.29 6 0.04,
n = 8, p < 0.05) and significantly increased it after
3–4 hr (0.75 6 0.1, n = 8, p < 0.01, Figure 5B).
Next, to investigate whether AMPAR function and/or
number was modified with orexin A treatment, we exam-
ined AMPAR-mediated miniature EPSCs (mEPSCs),
a standard method for determining the locus of synaptic
change. Compared to untreated neurons, orexin A (100
nM) caused a significant increase in both amplitude (Fig-
ures 6C, 6D, and 6F) and frequency (Figures 6C, 6E, and
6G) 3–4 hr after application (24 6 1.6 pA; 2.4 6 0.5 Hz;
n = 7 versus control: 13 6 1.3 pA; 0.93 6 0.16 Hz; n = 7;
Figure 6A), but not at 15 min (15 6 1.7 pA; 0.9 6 0.1 Hz;
n = 6, p < 0.05, Figure 6B). Interestingly, the increase in
AMPAR mEPSC amplitude observed 3–4 hr after orexin A
application was significantly reduced when the NMDAR
antagonist APV (50 mM) was applied 3 min prior and
during orexin application (16 6 0.6 pA, Figure 6D, n = 7,
p > 0.05). However, frequency remained elevated
over controls 3–4 hr after orexin A application (1.6 6
0.3 Hz, Figure 6E, n = 7, p < 0.05), suggesting that orexin
application may also produce a distinct presynaptic
effect.When AMPA (2 mM for 30 s) in the presence of cyclo-
thiazide (100 mM; to reduce AMPAR desensitization)
was superfused onto neurons 15 min after orexin A
(100 nM) treatment, there was no significant increase
in AMPAR-induced current (2243 6 79 pA, n = 5) com-
pared with untreated neurons (2210 6 64, n = 9,
Figure 6H, p > 0.05). AMPAR-induced currents signifi-
cantly increased 3–4 hr after orexin A (100 nM) treatment
(2367 6 63 pA, n = 6, p < 0.05, Figure 6I, t test of peak
control versus peak orexin).
To examine changes in number or function of
NMDARs after orexin treatment, we recorded NMDAR
mEPSCs in buffer without Mg2+ and in the presence
CNQX (10 mM), glycine (20 mM), and lidocaine (500 mM).
Orexin A (100 nM) caused a significant increase in ampli-
tude in NMDAR mEPSCs 15 min after application (17.16
0.7 pA, n = 8, Figures 7B, 7D, and 7F) compared to un-
treated neurons (14.2 6 0.9 pA, n = 8, Figures 7A, 7D,
and 7F) or at 3–4 hr after orexin A application (13.9 6
0.5 pA, n = 7, Figures 7C, 7D, and 7F). Our results
show that the frequency of NMDAR mEPSCs was not
significantly altered by orexin A treatment (control:
2.1 6 0.3, 15 min: 2.1 60.3, 3–4 hours: 2.5 6 0.4, p >
0.05, Figures 7E and 7G).
As a final test to determine at what time point after
orexin treatment NMDARs were altered, we bath applied
NMDA (50 mM, 30 s) and recorded the change in holding
current. We observed a significant increase in NMDA-in-
duced current 15 min after orexin A (100 nM) application
(orexin A: 3446 27 pA, n = 7; control: 2456 43, n = 9, p <
0.05, Figure 7H), but not after 3–4 hr (orexin A: 3056 59,
n = 6; p > 0.05, Figure 7I). Taken together, these results
indicate that the number or function or both of AMPARs
are altered 3–4 hr after orexin A exposure, suggest-
ing that orexin A may cause a late-phase long-term
potentiation.
Orexin Signaling in the Ventral Tegmental Area
Is Required for Behavioral Sensitization to Cocaine
Because orexin A potentiated NMDAR-mediated synap-
tic responses in dopamine neurons of the VTA, and syn-
aptic plasticity at excitatory synapses after chronic co-
caine treatment was blocked with coinjections of the
OXR1 antagonist, we hypothesized that orexin receptor
Orexin A Mediates Dopamine Neuron Plasticity
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Orexin A (100 nM) was bath applied for 5 min and then recorded 15 min or 3–4 hr after orexin A application. Example traces of mEPSCs and
averaged mEPSCs from the same cell are shown (A) without orexin. (B) 15 min after or (C) 3–4 hr after orexin A application. Scale bars,
20 pA, 100 ms for mEPSC traces and 5 pA, 5 ms for averaged mEPSCs. (D) Neurons recorded 3–4 hr after orexin A application had increased
AMPAR mEPSC amplitude (n = 7, filled bars) compared to 15 min after (n = 6, shaded bars) or controls (n = 7, open bars, p < 0.05). The
orexin-mediated increase in amplitude at 3–4 hr was blocked when APV (50 mM) was applied 3 min prior to and during orexin application
(n = 7, dotted bars, p > 0.05). (E) AMPAR mEPSC frequency increased in neurons recorded 3–4 hr after orexin A application (n = 7) compared
to 15 min after (n = 6) or control (n = 7) conditions (p < 0.05). AMPAR mEPSC frequency at 3–4 hr was also elevated with prior APV treatment
(n = 7, p < 0.05). (F) A cumulative probability plot of amplitude for mEPSCs from example cells in control (black), 15 min (red), 3–4 hr (blue), or
3–4 hr after orexin A (100 nM) application with prior APV (50 mM) treatment (green). (G) A cumulative probability of frequency plot for mEPSCs
from example cells in control, 15 min, 3–4 hr, or 3–4 hr after orexin application with prior APV (50 mM) treatment (green). (H) Changes in holding
current were measured after bath application of AMPA (2 mM) in the presence of cyclothiazide (100 mM). There was no change in current when
AMPA (2 mM) was superfused onto slices for 30 s between controls (n = 9) and neurons recorded 15 min after orexin A application (n = 5, p > 0.05).
(I) Bath application of AMPA (2 mM) elicited a greater inward current in neurons recorded 3–4 hr after orexin A application compared to controls
(n = 6, p < 0.05). Error bars represent SEM.activation contributes to the development of behavioral
sensitization to cocaine.
To determine whether orexin signaling plays a role in
behavioral sensitization to cocaine, we injected either
the OXR1 antagonist SB 334867 (10 mg/kg, i.p.) or vehi-
cle, 15 min prior to injecting cocaine (15 mg/kg, i.p) or
saline (0.9%), and then placed rats in an open-field
chamber to measure locomotor activity for 1 hr each
day for 5 days. Interestingly, SB 334867 significantly
blocked the development of sensitization, as the dis-
tance traveled on day 5 was 8504 6 2564 cm comparedto 20347 6 5643 cm in cocaine-only-treated rats (Fig-
ure 8A, n = 13, p < 0.05). There was no significant differ-
ence in locomotor activity of cocaine-treated rats on day
1 between SB334867 (35796 1079 cm, n = 11) and vehi-
cle (56926 1579 cm, n = 13) administered rats (p > 0.05).
Further, SB 334867 did not reduce baseline locomotor
activity (Figure 8A, n = 13, p > 0.05).
We have provided evidence that orexin A signaling
is required for acquisition of cocaine sensitization. How-
ever, our experiments have not answered the question
of whether orexin A contributes to the expression of
Neuron
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Orexin A (100 nM) was bath applied for 5 min and then recorded 15 min or 3–4 hr after orexin A application. NMDAR mEPSCs were recorded in
Mg2+-free aCSF with 20 mM glycine, 10 mM CNQX, and 500 mM lidocaine when the neurons were voltage clamped at240 mV. Example traces of
mEPSCs were recorded (A) without orexin, (B) 15 min after, or (C) 3–4 hr after orexin A application. Scale bars, 50 pA, 100 ms. Below each con-
dition is an averaged mEPSC from each of the above example neurons. Scale bars, 5 pA, 5 ms. (D) Orexin A increased NMDAR mEPSC amplitude
15 min after orexin A (100 nM) application (n = 8) compared to controls (n = 8) or 3–4 hr after orexin A application (n = 7, p < 0.05). (E) NMDAR
mEPSC frequency was not altered by orexin A (100 nM) application (p>0.05). (F) A cumulative probability of amplitude plot for NMDAR mEPSCs
from a single cell in control (black), 15 min (red), or 3–4 hr (blue) after orexin application. (G) A cumulative probability of frequency plot for mEPSCs
from a single cell in control (black), 15 min (red), or 3–4 hr (blue) after orexin application. (H) Changes in holding current were measured after
NMDA (50 mM, 30 s) was bath applied to VTA slices. NMDA-induced current was significantly greater in neurons 15 min after orexin A treatment
(n = 7) compared to controls (n = 9, p < 0.05). (I) There was no difference in NMDA-induced current between controls and neurons 3–4 hr after
orexin A treatment (n = 6, p > 0.05). Error bars represent SEM.cocaine sensitization. Therefore, to determine whether
expression of cocaine sensitization requires release of
orexin acting at the OXR1 receptor, we injected the
OXR1 antagonist SB 334867 (10 mg/kg) with cocaine
(15 mg/kg) on day 6 into either cocaine-sensitized or
saline-treated rats. Locomotor activity on day 6 was not
significantly reduced by SB 334867 (Figure 8A, n = 7 in
each group, p > 0.05), indicating that while orexin signal-
ing is required for the development of cocaine sensitiza-
tion it is not required for its expression.
Our in vitro experiments indicated that VTA was an im-
portant site of action for orexin-induced plasticity. Thus,to determine whether OXR1 antagonist blockade of
locomotor sensitization to cocaine occurred through a
direct action in the VTA, we repeated cocaine-sensitiza-
tion experiments using a 7 day sensitization paradigm,
but microinjected the OXR1 antagonist (6 mg/hemi-
sphere) directly into the VTA prior to cocaine injection
(15 mg/kg). Figure 8B shows that daily intra-VTA injec-
tion of the OXR1 antagonist abolished the development
of locomotor sensitization to cocaine (Figure 8B; p >
0.05 in SB 334867-treated group, comparing day 7 and
day 1 locomotor activity). Control animals injected with
vehicle solution showed robust sensitization (Figure 8B;
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(A) Locomotor activity was assessed after i.p. administration of cocaine (squares, 15 mg/kg) or saline (circles) injections with SB 334867 (open
symbols, 10 mg/kg, i.p.) or vehicle (closed symbols, n = 13 for all groups to day 5). Vehicle-treated rats were injected with SB 334867 (10 mg/kg)
on day 6 (open circles, saline + SB 334867, n = 7; open squares, cocaine + SB 334867, n = 7).
(B) Rats received intra-VTA SB 334867 (6 mg/0.3 ml; open symbols) or vehicle (closed symbols) and were tested for locomotor activity after re-
ceiving i.p. injections of cocaine (squares: SB 334867, n = 12; vehicle, n = 12) on days 1–7. Control rats received saline (circles: SB 334867,
n = 10; vehicle, n = 8). Error bars represent SEM.
(C and D) Individual rats’ locomotor activity on days 1 and 7 for cocaine-treated rats in the presence (C) or absence (D) of intra-VTA SB 334867.
Arrows indicate mean locomotor distance.
(E) Reconstructed SB 334967 injection sites in the VTA are shown in coronal sections. Distance from bregma is shown to the right of each section
(in millimeters).p < 0.01, locomotor activity was significantly higher on
days 4–7 relative to day 1). Mean locomotor distance
was 34162 6 4477 cm on day 7 in control animals
(Figure 8C), compared with 19274 6 4559 cm in OXR1
antagonist-treated animals (Figure 8D), the latter value
not differing significantly from the locomotor distance
traveled on day 1. Similar to systemic injections (Fig-
ure 8A), a single intra-VTA injection of the OXR1 antago-
nist did not affect expression of pre-existing cocaine
sensitization in this control group (p > 0.05; data notshown). Taken together, our results indicate that OXR1
activation at dopaminergic neurons in the VTA is re-
quired for the development of behavioral sensitization
as well as for the induction of synaptic plasticity at excit-
atory synapses associated with sensitization.
Discussion
The data presented here establish a function for orexin
signaling as a critical substrate for plasticity of synaptic
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598inputs to dopamine neurons of the VTA. Four observa-
tions support this conclusion. First, in vitro application
of orexin A induces potentiation of NMDAR responses
in VTA dopamine neurons. Second, the OXR1 receptor
antagonist SB 334867 blocks induction of cocaine-
induced potentiation of excitatory inputs onto VTA neu-
rons. Third, orexin A causes late-phase increases in
AMPAR-mediated synaptic transmission. Fourth, micro-
injection of SB 334867 directly into the VTA blocks the
development of cocaine-induced locomotor sensitiza-
tion. These data provide evidence that orexin signaling
pathways play an important role in drug-induced neural
plasticity contributing to cocaine addiction.
Orexin A Enhances Synaptic Strength
in VTA Dopamine Neurons
Orexin A potentiated NMDAR EPSCs in dopamine neu-
rons via activation of OXR1 receptors and stimulation
of PKC/PLC signal transduction pathways. These re-
sults are consistent with orexin A-mediated PLC and
PKC activation of Ca2+ signaling, observed in isolated
VTA neurons (Uramura et al., 2001) through OXR1, that
are coupled to Gq-type Ga proteins (Zhu et al., 2003).
The orexin A-mediated synaptic plasticity resulted
from the translocation of NMDARs to the synapse. Be-
cause we observed an increase in NMDAR-evoked
EPSCs after orexin treatment compared to controls after
blocking all synaptic and extrasynaptic NMDARs, it ap-
pears that the orexin-mediated potentiation of NMDARs
is mediated, at least in part, by movement of NMDARs
from intracellular compartments to the synapse. Move-
ment of NMDARs to synaptic sites could provide a
mechanism for rapidly enhancing synaptic strength
(Tovar and Westbrook, 2002). This is consistent with
orexin A potentiation of synaptic strength by movement
of NMDARs into the synapse with a time course on the
order of minutes.
Experiments with orexin A application in the presence
of NMDAR subunit inhibitors suggest that NR2A-
containing NMDARs play a significant role in enhancing
NMDAR-mediated responses. In rats aged P21 or older,
mRNA and protein for NR2A, NR2B, and to a lesser ex-
tent NR2C and NR2D has been observed in midbrain
(Monyer et al., 1994; Dunah et al., 1996); however, NR2A
was not observed in the rat substantia nigra (Jones and
Gibb, 2005; Standaert et al., 1994). NMDAR subunit
composition in rat VTA has not been reported. In VTA
punches, our lab has found protein for NR2A, NR2B,
and NR2C (B. Schilstrom and A. Bonci, 2002, Soc. Neu-
rosci., abstract). NR2D could not be detected due to the
lack of selectivity of the antibody. The selectivity of the
NR2A/C antagonist has been questioned (Berberich
et al., 2005; Weitlauf et al., 2005) because preapplication
of 0.4 mM NVP-AAM077 has been demonstrated to in-
hibit NR2B-containing NMDARs (Weitlauf et al., 2005).
However, in our experiments, three lines of evidence
suggest that orexin A can recruit NMDAR subtypes.
First, NVP-AAM077 blocked NMDAR potentiation post-
orexin A application. Second, Zn2+, a selective inhibitor
of NR2A-containing NMDARs at nanomolar concentra-
tions, blocked orexin-mediated potentiation of NMDARs.
Finally, the NR2B subunit antagonist ifenprodil exerted
no significant effect on orexin A-mediated potentia-
tion of NMDAR EPSCs. The residual orexin-mediatedNMDAR potentiation observed in the presence of NVP-
AAM077 or Zn2+ was blocked by coapplication of ifen-
prodil, NVP-AAM077, and the NR2C/D-preferring antag-
onist PPDA. These data suggest that although orexin A
primarily potentiates NR2A-containing NMDAR recep-
tors, it can also potentiate other NR2 subunits to a lesser
extent. Thus, orexin A appears to be enhancing synaptic
plasticity in the VTA primarily by promoting increased
NR2A-containing NMDARs at the synapse.
Our results indicate thatacute orexin A application pro-
duces a PLC/PKC-dependent potentiation of NMDAR-
mediated responses, while AMPAR-mediated re-
sponses are unaffected. Further, we have shown that
in vivo exposure tococaine produces adelayed potentia-
tion of AMPARs but not NMDARs (Ungless et al., 2001;
Borgland et al., 2004; present study), which is blocked
by the OXR1 antagonist SB 334867. Therefore, it is pos-
sible that the orexin-mediated potentiation of NMDARs
facilitates the induction of synaptic plasticity, which in-
volves an increase in AMPAR-mediated synaptic trans-
mission. Although we did not see a change in AMPAR-
evoked EPSCs, mEPSCs, or AMPAR current changes
at 15 min after orexin application, by 3–4 hr a robust
increase in AMPAR-mediated synaptic transmission
had developed. This late-phase increase in postsynaptic
AMPAR-mediated synaptic transmission was blocked
when the NMDAR antagonist APV was coadministered
with orexin A. The increase in AMPAR mEPSC frequency
was not blocked by APV, suggesting that an NMDAR-in-
dependent delayed presynaptic effect may also occur.
Consistent with our results, orexin A has previously
been shown to enhance long-term potentiation when ap-
plied directly to the dentate gyrus in anesthetized rats
(Wayner et al., 2004). Increased synaptic efficacy may
be due to insertion of new AMPARs into the synaptic
membrane (Malinow et al., 2000; Lu et al., 2001) or other
structural or functional modifications at existing AMPAR
channels (Benke et al., 1998; Derkach et al., 1999). Addi-
tionally, late-phase long-term potentiation occurring
3–5 hr after stimulation is dependent on postsynaptic
protein synthesis (Nayak et al., 1998; Grosshans et al.,
2001). Therefore, the delayed increase in AMPAR-
mediated synaptic transmission after orexin A applica-
tion may represent late-phase long-term potentiation.
Orexin May Play a Critical Role in Addiction
The present study demonstrates that orexin A produces
long-lasting plasticity at excitatory synapses of dopa-
mine neurons in the VTA. Synaptic plasticity in the VTA
has been suggested to play an important role in the be-
havioral consequences of in vivo exposure to drugs of
abuse (Robinson and Berridge, 1993; Overton and Clark,
1997; Ungless et al., 2001; Saal et al., 2003). From a func-
tional perspective, NMDARs perform two major roles in
VTA dopamine neurons: they are necessary for the in-
duction of in vitro long-term potentiation (Bonci and
Malenka, 1999; Overton et al., 1999) and they promote
burst firing of dopamine neurons (Johnson et al., 1992;
Overton and Clark, 1992; Komendantov et al., 2004).
Previous studies have suggested that burst firing of VTA
dopamine neurons encodes the occurrence of salient
stimuli (Schultz, 2002). As a consequence, burst firing in-
creases extracellular dopamine in the projection areas
more efficiently than when dopamine neurons fire
Orexin A Mediates Dopamine Neuron Plasticity
599regularly spaced trains of action potentials (Gonon,
1988; Komendantov et al., 2004). Although dopamine
neurons generally fire in a pacemaker-like fashion in vitro,
burst-firing patterns, similar to what has been observed
in vivo, can be reproduced by bath application of
NMDA (Komendantov et al., 2004). Thus, an increase in
synaptic efficacy, including the synaptic potentiation
observed in this study, may contribute to the increase
in dopamine cell firing rate. This change could enhance
reinforcement, as it has been proposed that dopamine
neuronal firing represents a teaching signal (Garris
et al., 1999; Schultz, 2002). Accordingly, orexin A has
been demonstrated to increase firing rate and in some
cases cause burst firing of VTA dopamine neurons in
rat brain slices (Korotkova et al., 2003), although it re-
mains to be determined whether this firing is dependent
on potentiation of glutamatergic synapses. Orexin po-
tentiation of NMDAR currents in dopamine neurons
may represent a crucial process underlying stimulation
of locomotor activity to achieve goal-directed behavior.
For example, fasted animals increase wakefulness
and locomotor activity via activation of orexin neurons
(Yamanaka et al., 2003), and this locomotor activation
may be dopamine dependent (Wisor et al., 2001). We
have demonstrated that orexin A signaling is required
for the acquisition of cocaine sensitization, a paradigm
for craving, suggesting that by blocking orexin signaling
in the VTA, we may be perturbing cocaine’s motivational
significance and reducing the rat’s drive for cocaine
seeking.
Animals with lesions in the LH exhibit hypophagia and
somnolence (Levitt and Teitelbaum, 1975; Bernardis and
Bellinger, 1996), suggesting important roles for the LH in
the control of motivated behavior. The LH has also been
implicated in motivation associated with reward (Wise
1996; Di Leone et al., 2003). Direct electrical stimulation
of the LH is so intensely rewarding to rats that they will
starve themselves when limited access to such stimula-
tion is given concurrently with limited access to food
(Routtenberg and Lindy, 1965). Furthermore, drugs of
abuse potentiate the rewarding effects of LH self-stimu-
lation (Wise, 1996). Recent studies have shown that
some of these LH functions may require orexin neurons,
as orexin knockout mice show reduced morphine de-
pendence (Georgescu et al., 2003). Additionally, activa-
tion of orexin neurons is strongly linked to preferences
for cues associated with drug and food reward, as
both activation of orexin neurons and intra-VTA admin-
istration of orexin A leads to a reinstatement of an extin-
guished conditioned place preference to morphine (Har-
ris et al., 2005). Therefore, it is a strong possibility that
orexin A-induced synaptic plasticity in the VTA is medi-
ating reward-seeking behaviors. The findings presented
here establish a potential mechanism for the role of
orexin signaling in plasticity related to addiction. Our re-
sults demonstrate that orexin A induces synaptic plas-
ticity in dopaminergic VTA neurons; moreover, this
form of synaptic plasticity is likely an important sub-
strate of behaviors relevant to addiction, as we show
that activation of OXR1 receptors in the VTA is neces-
sary for the development of cocaine-mediated behav-
ioral sensitization. Thus, orexin receptors may provide
novel pharmacotherapeutic targets for motivational dis-
orders such as addiction.Experimental Procedures
Electrophysiology
All the electrophysiological recordings were performed in rats rang-
ing from P21 to P30. Briefly, rats were anesthetized with halothane
and sacrificed. Horizontal sections of the VTA (230 mM) were pre-
pared with a vibratome (Leica, Nussloch, Germany). Slices were
placed in a holding chamber and allowed to recover for at least
1 hr before being placed in the recording chamber and superfused
with bicarbonate-buffered solution (ACSF) saturated with 95% O2/
5% CO2 and containing (in mM): 119 NaCl, 1.6 KCl, 1.0 NaH2PO4,
1.3 MgCl2, 2.5 CaCl2, 26.2 NaHCO3, and 11 glucose (at 32ºC–34ºC).
Picrotoxin (100 mM) was added to block GABAA receptor-mediated
inhibitory postsynaptic currents. Cells were visualized using infrared
differential interference contrast video microscopy. Whole-cell volt-
age-clamp recordings were made using an Axopatch 1D amplifier
(Axon Instruments, Union City, CA). Electrodes (2.8–4.0 MU) con-
tained (in mM): 120 cesium methansulfonate, 20 HEPES, 0.4 EGTA,
2.8 NaCl, 5 TEA-Cl, 2.5 MgATP, and 0.25 NaGTP (pH 7.2–7.3) (270–
285 mOsm). Series resistance (10–40 MU) and input resistance
were monitored online with a 4 mV depolarizing step (50 ms) given
just after every afferent stimulus. Dopaminergic VTA neurons were
identified by the presence of a large Ih current (Lacey et al., 1990;
Johnson and North, 1992) and, in some cases, tyrosine hydroxylase
labeling. A bipolar stimulating electrode was placed 100–300 mm ros-
tral to the recording electrode and was used to stimulate excitatory
afferents at 0.1 Hz. Neurons were voltage clamped at –70 mV and
+40 mV to record AMPAR- and NMDAR-mediated EPSCs. EPSCs
were filtered at 2 kHz, digitized at 5–10 kHz, and collected online
using Igor Pro software (Wavemetrics, Lake Oswego, OR). NMDAR
or AMPAR traces were constructed by averaging 12 EPSCs (120 s)
elicited at +40 mV or at 270 mV. NMDAR amplitude was measured
20 ms after the stimulus artifact, when the EPSC is primarily NMDAR
mediated.
To calculate the AMPAR/NMDAR ratio, an average of 12 EPSCs at
+40 mV was computed before and after application of the NMDAR
blocker AP5 (50 mM) for 5 min. NMDAR responses were calculated
by subtracting the average response in the presence of AP5 (AMPAR
only) from that seen in its absence; the peak of the AMPAR EPSC
was divided by the peak of the NMDAR EPSC to yield an AMPAR/
NMDAR ratio.
AMPAR mEPSCs were recorded in cells voltage clamped at 270
mV in lidocaine (500 mM), APV (50 mM), and sucrose (100 mM).
NMDAR mEPSCs were recorded at 240 mV in Mg2+-free external
solution with lidocaine (500 mM), glycine (20 mM), and CNQX
(10 mM). mEPSCs were collected using Clampex (Axon Instruments)
and analyzed using Mini Analysis Program (Synaptosoft). Detection
criteria were set at >10 pA, <1 ms rise-time, and <3 ms decay-time
for AMPAR mEPSCs and >10 pA, <1 ms rise-time, and <10 ms
decay-time for NMDAR mEPSCs. mEPSC traces were recorded
while sampling every 10 ms, the images were filtered at 5 kHz.
Averaged mEPSCs were constructed using Mini Analysis Program
(Synaptosoft).
Treatment Regimen and Locomotor Activity
Male Sprague-Dawley Rats (P21–P30; Charles River, NC) were sin-
gly housed with food and water available ad libitum. A 12 hr light/
dark cycle was used, with the lights on at 7:00 A.M. All cocaine injec-
tions and behavioral testing were performed during the light cycle
for consecutive days. The four treatment groups consisted of rats
given five daily i.p. injections of SB 334867 (10 mg/kg) 15 min pre-
ceding i.p. injection of cocaine (15 mg/kg) or saline (0.9% NaCl), or
i.p. injections of vehicle (10% DMSO and 25% b-hydroxy cyclodex-
trin in saline) 15 min preceding i.p. injection of cocaine or saline. All
animals were habituated to the photocell boxes (Med Associates, St.
Albans, VT) for 2 hr prior to the start of the experiment. All animals
were further habituated to the photocell boxes for 30 min prior
to 60 min testing session. Locomotor activity was measured in
17 inch 3 17 inch chambers lined with three 16-beam I/R arrays. A
50 ms scanning rate was used for measurement of beams broken.
Distance traveled was measured using Open Field Activity Software
(Med Associates, Inc) and analyzed for estimates of locomotion
based on the movement of a given distance and resting delay (move-
ment in a given period of time).
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Male Sprague-Dawley rats (250 grams) were implanted with bilateral
cannulae directed at the VTA (AP,25.2; ML,60.5; DV,28.0). Follow-
ing recovery from surgery, animals were tested in a cocaine-sensiti-
zation assay similar to that used for systemic administration of the
OXR1 antagonist, but with two changes: a 7 day sensitization para-
digm was used, and the OXR1 antagonist SB 334867 was microin-
jected directly into the VTA (6 mg/hemisphere in 300 nL solution com-
posed of 10% DMSO in water). All other methods for habituation and
data collection were identical to that described above. Rats were
deeply anesthetized with pentobarbital and perfused with a 10%
formaldehyde solution. Brains were cryoprotected in 25% sucrose,
40 mm coronal sections were cut on a freezing microtome, and sec-
tions were mounted, dried, and coverslipped. Injection sites were
located under a light microscope and recorded on atlas figures
adapted from Paxinos and Watson (1997).
Data Analysis
All values are expressed as mean 6 SEM. Statistical significance
was assessed using two-tailed Student’s t tests or a one-way
ANOVA for multiple group comparisons. A Bonferroni post hoc
test following an ANOVA was used to test significant differences be-
tween multiple groups.
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